Madrigal Pharmaceuticals Inc.
Organization details
- Legal name
- Madrigal Pharmaceuticals Inc.
- Former names
- Synta Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- West Conshohocken
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MDGL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001157601
Board of directors
-
Daniel J. Brennan · DirectorSince 2025
- Since 2023
-
Fred B. Craves · DirectorSince 2023
-
Jacqualyn A. Fouse · DirectorSince 2025
-
James M. Daly · DirectorSince 2023
-
John C. Reed · DirectorSince 2026
- Since 2023
-
Kenneth Bate · DirectorSince 2023
-
Paul A. Friedman · Director · Chief Executive OfficerSince 2023
-
Raymond Cheong · DirectorSince 2023
-
Rebecca Taub · Director · Pres., R&D, and CMOSince 2023
-
Richard S. Levy · DirectorSince 2023
-
William John Sibold · Director · President and CEOSince 2023
Chief executives
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.6%
-
96.6%
-
99.4%
Board connections
8 of this board's directors also sit on 21 other boards. 20 are in the same sector.
-
ACADIA Pharmaceuticals Inc. Same sectorvia Felix Baker, James M. Daly and Julian Baker
-
Incyte Corp. Same sectorvia Felix Baker, Jacqualyn A. Fouse and Julian Baker
-
Kiniksa Pharmaceuticals International plc Same sectorvia Felix Baker, Julian Baker and Richard S. Levy
-
Kodiak Sciences Inc Same sectorvia Felix Baker, Julian Baker and Richard S. Levy
-
Prelude Therapeutics Incorporated Same sectorvia Felix Baker, Julian Baker and Paul A. Friedman
-
vTv Therapeutics Inc. Same sectorvia Felix Baker, Julian Baker and Raymond Cheong
-
BeOne Medicines Ltd. Same sectorvia Felix Baker and Julian Baker
-
Bicycle Therapeutics plc Same sectorvia Felix Baker and Julian Baker
-
DBV Technologies S.A. Same sectorvia Felix Baker and Julian Baker
-
Denali Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Immunocore Holdings plc Same sectorvia Felix Baker and Julian Baker
-
Kymera Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Neurogene Inc. Same sectorvia Felix Baker and Julian Baker
-
Replimune Group Inc. Same sectorvia Felix Baker and Julian Baker
-
TScan Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Agios Pharmaceuticals Inc. Same sectorvia Jacqualyn A. Fouse
-
Cytokinetics Incorporated Same sectorvia James M. Daly
-
Halozyme Therapeutics Inc. Same sectorvia James M. Daly
-
Protara Therapeutics Inc. Same sectorvia Richard S. Levy
-
Vertex Pharmaceuticals Incorporated Same sectorvia Daniel J. Brennan
- via Daniel J. Brennan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $35,023,032
- 5 purchases by 1 insider
- Sold, last 12 months
- $73,883,995
- 192 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | Kelley Shannon T Officer (General Counsel) | Open-market sale | −1,077 | $400.00 | $430,800 |
| Nov 6, 2026 | BAKER BROS. ADVISORS LP Director | Open-market purchase | +60,400 | $383.02 | $23,134,106 |
| Nov 6, 2026 | BAKER BROS. ADVISORS LP Director | Open-market purchase | +13,740 | $388.29 | $5,335,105 |
| Nov 6, 2026 | BAKER BROS. ADVISORS LP Director | Open-market purchase | +2,000 | $396.61 | $793,220 |
| Nov 4, 2026 | BAKER BROS. ADVISORS LP Director | Open-market purchase | +5,586 | $366.99 | $2,050,018 |
| Nov 4, 2026 | BAKER BROS. ADVISORS LP Director | Open-market purchase | +10,080 | $368.11 | $3,710,583 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −60 | $533.09 | $31,985 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −106 | $534.06 | $56,610 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −218 | $535.94 | $116,835 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −160 | $537.62 | $86,019 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −687 | $540.59 | $371,385 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −368 | $541.64 | $199,324 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −1,202 | $542.60 | $652,205 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −1,539 | $544.02 | $837,247 |
| Sep 11, 2026 | William John Sibold Director, Officer (President and CEO) | Open-market sale | −761 | $544.83 | $414,616 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Madrigal Pharmaceuticals Inc.
Who is the CEO of Madrigal Pharmaceuticals Inc.?
William John Sibold has been Madrigal Pharmaceuticals Inc.'s President and CEO since September 2023.
How many directors are on Madrigal Pharmaceuticals Inc.'s board?
Madrigal Pharmaceuticals Inc.'s board has 13 directors: Daniel J. Brennan, Felix Baker, Fred B. Craves, Jacqualyn A. Fouse, James M. Daly, John C. Reed, Julian Baker, Kenneth Bate, Paul A. Friedman, Raymond Cheong and 3 others.
Are Madrigal Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, Madrigal Pharmaceuticals Inc. insiders bought $35.0 million of shares in 5 purchases and sold $73.9 million of shares in 192 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="madrigal-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.